Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$7.50
+1.2%
$5.80
$4.09
$17.24
$160.33M0.76286,451 shs243,932 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.43
-3.4%
$12.84
$5.22
$27.38
$156.47M0.43145,939 shs76,404 shs
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
$1.04
-4.6%
$0.92
$0.71
$3.83
$137.58M-0.111.29 million shs617,864 shs
Sernova Corp. stock logo
SEOVF
Sernova
$0.13
+5.1%
$0.14
$0.10
$0.29
$41.32M1.0833,598 shs1,469 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
0.00%+0.40%+39.66%+12.78%-43.61%
LifeVantage Co. stock logo
LFVN
LifeVantage
0.00%-0.72%-1.43%-27.01%+66.40%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
0.00%-11.11%+28.57%-8.77%-70.70%
Sernova Corp. stock logo
SEOVF
Sernova
0.00%+4.57%-17.78%+4.05%-40.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
3.7014 of 5 stars
3.41.00.04.72.02.50.0
LifeVantage Co. stock logo
LFVN
LifeVantage
3.9842 of 5 stars
3.50.01.72.72.91.71.3
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
3.8838 of 5 stars
3.21.00.04.22.61.71.3
Sernova Corp. stock logo
SEOVF
Sernova
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.80
Moderate Buy$18.00140.00% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50145.37% Upside
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
2.33
Hold$3.00188.46% Upside
Sernova Corp. stock logo
SEOVF
Sernova
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SEOVF, LFVN, RAPT, and ENTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.00
5/22/2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00
5/22/2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$6.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$64.46M2.49N/AN/A$5.24 per share1.43
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.70$0.65 per share19.03$2.38 per share5.22
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
$1.53M89.92N/AN/A$4.27 per share0.24
Sernova Corp. stock logo
SEOVF
Sernova
N/AN/AN/AN/A($0.03) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/4/2025 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6922.20N/A3.46%34.29%15.04%8/27/2025 (Estimated)
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%8/6/2025 (Estimated)
Sernova Corp. stock logo
SEOVF
Sernova
-$23.65M-$0.04N/AN/AN/AN/A-283.67%N/A

Latest SEOVF, LFVN, RAPT, and ENTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/13/2025Q2 2025
Sernova Corp. stock logo
SEOVF
Sernova
N/A-$0.01N/A-$0.01N/AN/A
5/12/2025Q2 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million
5/8/2025Q1 2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-$0.31-$0.08+$0.23-$0.08N/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.45%N/A26.09%3 Years
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
N/AN/AN/AN/AN/A
Sernova Corp. stock logo
SEOVF
Sernova
N/AN/AN/AN/AN/A

Latest SEOVF, LFVN, RAPT, and ENTA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
5.47
5.47
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
N/A
9.90
9.90
Sernova Corp. stock logo
SEOVF
Sernova
N/A
0.32
0.32

Institutional Ownership

CompanyInstitutional Ownership
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
99.09%
Sernova Corp. stock logo
SEOVF
Sernova
N/A

Insider Ownership

CompanyInsider Ownership
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
13.89%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
2.36%
Sernova Corp. stock logo
SEOVF
Sernova
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16021.38 million18.37 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
80132.29 million32.65 millionOptionable
Sernova Corp. stock logo
SEOVF
Sernova
N/A328.49 millionN/ANot Optionable

Recent News About These Companies

Sernova Appoints Jonathan Rigby as Interim Chair
Chair of Sernova Biotherapeutics Resigns
Sernova names Pericles Calias as CDO and head of R&D

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$7.50 +0.09 (+1.21%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$7.50 0.00 (0.00%)
As of 06/13/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.43 -0.44 (-3.42%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$13.62 +1.20 (+9.61%)
As of 06/13/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

RAPT Therapeutics stock logo

RAPT Therapeutics NASDAQ:RAPT

$1.04 -0.05 (-4.59%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.04 0.00 (-0.10%)
As of 06/13/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Sernova stock logo

Sernova OTCMKTS:SEOVF

$0.13 +0.01 (+5.10%)
As of 06/13/2025 10:16 AM Eastern

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.